TheraRadar
← Back
Data updated: Jun 28, 2026

PURACAP LABS BLU

Generics
Pharmaceuticals

PURACAP LABS BLU is a generic drug manufacturer with 6 FDA-approved products.

2016
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

PURACAP LABS BLU's Key Drugs

PURACAP LABS BLU's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PURACAP LABS BLU's Recent FDA Approvals

New NDA/BLA approvals for PURACAP LABS BLU over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PURACAP LABS BLU's Therapeutic Areas

Disease areas where PURACAP LABS BLU has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PURACAP LABS BLU Pipeline Snapshot

Active clinical trials for PURACAP LABS BLU across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling